Adaptive Biotechnologies COO sells 35,643 shares
The President and COO's option exercises and share sales occurred on the same dates under a plan adopted November 18, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp President and COO Julie Rubinstein exercised 11,881 stock options on each of November 4, 5 and 6, 2026, at $12.14 per share, acquiring 35,643 common shares in total. She sold 35,643 common shares in reported transactions over those dates at weighted-average prices from $25.78 to $27.88 per share. The transactions were made under a Rule 10b5-1 trading plan adopted November 18, 2025; the options were fully vested and exercisable.
Insider Trade Summary 10b5-1
Exercise and Sale: 35,643 shares ($522K approx. pre-tax spread)
Exercise and Sale
13 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
35,643 shs ($954K)
Approx. gross sale proceeds
$954K
Approx. exercise cost
$433K
Approx. pre-tax spread
$522K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F9 | 11,881 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 11,881 | $12.14 | $144K |
| Sale | Common Stock F1, F7 | 8,400 | $27.32 | $229K |
| Sale | Common Stock F1, F8 | 3,481 | $27.88 | $97K |
| Exercise | Stock Option (right to buy) F1, F9 | 11,881 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 11,881 | $12.14 | $144K |
| Sale | Common Stock F1, F4 | 5,926 | $26.10 | $155K |
| Sale | Common Stock F1, F5 | 5,455 | $26.88 | $147K |
| Sale | Common Stock F1, F6 | 500 | $27.70 | $14K |
| Exercise | Stock Option (right to buy) F1, F9 | 11,881 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 11,881 | $12.14 | $144K |
| Sale | Common Stock F1, F2 | 4,000 | $25.78 | $103K |
| Sale | Common Stock F1, F3 | 7,881 | $26.60 | $210K |
Holdings After Transaction:
Stock Option (right to buy) — 58,990 contracts (Direct);
Common Stock — 377,802 shares (Direct)
Footnotes (9)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F5. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F6. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F7. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F8. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F9. The option is fully vested and exercisable.
Key Figures
Common shares acquired upon exercise: 35,643 shares
Common shares sold: 35,643 shares
Exercise price: $12.14 per share
+2 more
5 metrics
Common shares acquired upon exercise
35,643 shares
11,881 shares on each of November 4, 5 and 6, 2026
Common shares sold
35,643 shares
Seven reported transactions on November 4, 5 and 6, 2026
Exercise price
$12.14 per share
Reported for the option exercises
Reported weighted-average sale prices
$25.78–$27.88 per share
Prices reported for the sales on November 4, 5 and 6, 2026
Option expiration date
March 4, 2032
Expiration date reported for the stock options
Key Terms
Rule 10b5-1 trading plan, weighted average price, fully vested and exercisable
3 terms
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"price reported for this transaction is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
fully vested and exercisable technical
"The option is fully vested and exercisable."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were the terms of Julie Rubinstein's ADPT option exercises?
She exercised 11,881 options on each of November 4, 5 and 6, 2026, at $12.14 per share. The options were fully vested and exercisable and expire March 4, 2032. The transactions were made under a Rule 10b5-1 trading plan adopted November 18, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
